Compare Cenovus Energy Inc (CVE) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Davita Inc — how do they compare? Cenovus Energy Inc trades at $31.49 (market cap $56.66B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Cenovus Energy Inc is far larger — about 5× Davita Inc's market cap, and Cenovus Energy Inc pays a 2.03% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Davita Inc for 113 Days on average.
| CVE | DVA | |
|---|---|---|
Market Cap | $56.66B | $11.28B |
Volume | 7,667,753 | 650,294 |
Sector | Energy | Health |
52-Week High | $33.92 | $240.96 |
52-Week Low | $15.85 | $103.87 |
Typical Hold Time | 46 Days | 113 Days |
Enterprise Value | $62.61B | $24.00B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 0.8% today, with a bearish technical signal but strong fundamentals including a P/E of 12.14 and net income margin of 11.48%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q2 2026 met estimates. Cash flow from operations remains robust at $8.23B in 2025, though net cash flow was negative due to high capital expenditures. The stock is near its pivot point of $31, with support at $30 and resistance at $32.
Outlook: CVE offers value with attractive valuation ratios and solid profitability, but faces headwinds from volatile oil prices and capital-intensive operations. Analyst consensus is mixed with 40.7% buy ratings, suggesting cautious optimism amid energy sector uncertainty.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
